What is AOD 9604 peptide?

What is AOD 9604?

AOD 9604 is a derivative of human growth hormone (hGH) in the form of a cyclic peptide. Specifically, it is a modified fragment of hGH, comprising residues 177-191, which includes a di-sulfide bridge. The amino acid sequence of this peptide is cyclo(6,13)-H2N-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH (Ogru E., et al., 2000). It is reported that the C-terminal region of hGH (residues 177-191) constitutes a specific functional domain within the multifaceted hGH protein. AOD 9604 has been developed to replicate the fat-reducing effects of HGH while eliminating its detrimental side effects. In contrast to HGH, AOD 9604 precisely focuses on regions of the body with elevated fat accumulation, rendering it a more directed and potent approach for weight reduction. Through the stimulation of lipolysis, the inhibition of lipogenesis, and the modulation of fat metabolism, AOD 9604 facilitates the burning of additional fat and enhances caloric expenditure, ultimately resulting in more substantial weight loss within a shorter duration.

AOD 9604 benefits

AOD 9604 provides numerous advantages for individuals aiming to achieve weight loss and enhance their overall body composition. The following are the primary benefits associated with the use of AOD 9604:

1. Increased fat burning and weight loss

AOD 9604 activates the body's metabolic processes, which in turn increases the rate of fat oxidation while having no effect on blood glucose levels. This substance operates by directly engaging fat cells and intensifying lipolysis, thus promoting more pronounced weight reduction outcomes for individuals. Additionally, AOD 9604 does not provoke an increase in appetite, which simplifies the regulation of calorie consumption.

2. Improved bone and cartilage health

AOD 9604 has demonstrated the capability to facilitate bone and cartilage regeneration. It serves to augment bone strength and mitigate the risk of conditions including osteoarthritis and osteoporosis.

3. Enhanced muscle recovery

AOD 9604 may facilitate muscle recovery following exercise or injury, albeit with less direct evidence in comparison to its impacts on fat metabolism and cartilage repair.

AOD 9604 mechanism of action

AOD 9604 functions by stimulating the pituitary gland, akin to human growth hormone (HGH) and other growth hormones, to accelerate metabolism and facilitate weight reduction. Rapidly absorbed into the bloodstream, AOD 9604 produces immediate effects. It initiates lipolysis, the process of breaking down fat cells, and inhibits lipogenesis, the creation of new fat cells. This dual action facilitates more efficient fat burning and enhances overall weight loss. Additionally, AOD 9604 holds the potential to augment bone strength and mitigate degenerative changes in joints and muscles. The peptide AOD 9604 regulates body fat by mirroring the metabolic management mechanisms of growth hormones through the following means

1. Inhibiting the process of lipogenesis, which results in the production of fat and an elevation of triglyceride levels in the body.

2. Promoting lipolysis to decompose lipids and fats into fatty acids and glycerol.

3. Minimizing catabolic impacts.

4. Modulating insulin concentrations and blood glucose levels.

5. Enhancing caloric expenditure during physical exercise.

AOD 9604 peptide therapy

Studies have indicated that the AOD 9604 peptide has the potential to decrease body fat in the mid-abdominal region among obese, overweight, and individuals of average build. Additionally, it has been observed to possess regenerative capabilities, which include the enhancement of bone and cartilage repair. Due to these characteristics, AOD 9604 is a viable candidate for thorough investigation in the field of metabolic disorders, as well as for the treatment of conditions such as osteoporosis and joint degeneration.

What is AOD 9604 used for?

1. Weight loss and fat reduction

The most extensively studied function of AOD 9604 pertains to its capacity to facilitate weight loss through the enhancement of fat catabolism. For individuals who are battling obesity, it may offer a targeted approach to diminish fat accumulations, especially in persistent regions such as the abdomen or thighs.

2. Supporting joint and cartilage health

Certain studies propose the hypothesis that AOD 9604 may have beneficial effects on joint repair and the health of cartilage. While this particular field necessitates additional research, its anti-inflammatory characteristics could potentially render it a valuable asset for athletes or individuals experiencing joint-related problems.

3. Improvment of recovery times

By facilitating fat metabolism and potentially mitigating inflammation, AOD 9604 may assist individuals in achieving quicker recovery from physical exertion. This attribute could render it an attractive option for fitness enthusiasts or athletes aiming to enhance their performance.

AOD 9604 half life

According to reports, human growth hormone (hGH) has a plasma half-life of 21 minutes, whereas AOD 9604, as a fragment of hGH, exhibits a shorter half-life of 3 minutes in rats following intravenous injection. The rapid elimination of AOD 9604 may be attributed to enzymatic degradation(Margret I.M.,David K., 2014).

AOD 9604 vs tirzepatide

Tirzepatide serves as a dual agonist of the GIP and GLP-1 receptors, mimicking the actions of incretin hormones (GLP-1 and GIP) to regulate blood glucose levels and suppress appetite. In comparison to AOD 9604, Tirzepatide provides a more comprehensive therapeutic approach, focusing on weight reduction through appetite regulation and glucose control. The approval of Tirzepatide in multiple regions for the management of diabetes and obesity underscores its proven efficacy and safety. Conversely, the application of AOD 9604 is more specialized and frequently involves off-label use for specific fat reduction goals.

AOD 9604 vs tesamorelin

Tesamorelin is a synthetic form of growth hormone-releasing hormone (GHRH). It is used primarily to reduce belly fat in HIV patients with lipodystrophy, a condition characterized by abnormal fat distribution. Tesamorelin has shown efficacy in improving the aesthetic and clinical aspects of lipodystrophy by reducing visceral adiposity. Unlike AOD 9604, Tesamorelin indirectly affects fat metabolism by modulating the natural secretion of growth hormone.

AOD 9604 vs ipamorelin

Ipamorelin（NNC 26-0161）is a five-amino-acid research peptide that simulates the release of GH by activating the ghrelin receptors ( the growth hormone secretagogue receptors ) in the pituitary gland. It functions by enhancing the production of growth hormone, whereas AOD 9604 mimics certain effects of human growth hormone (hGH). These two compounds possess distinct mechanisms and effects. Specifically, Ipamorelin activates the GHS-R1a receptor in the pituitary gland, leading to an elevation in hGH levels. Therapy with Ipamorelin has been shown to augment serum GH, appetite, and body weight. Conversely, AOD 9604 seems to promote weight loss, primarily through reduction in fat mass. In summary, Ipamorelin appears to facilitate weight and muscle gain, whereas AOD 9604 may serve as an agent for weight reduction.

AOD 9604 vs cjc 1295

cjc 1295 is a research peptide that consists of the initial 29 amino acids located at the N-terminus of the endogenous growth hormone-releasing hormone (GHRH). These 29 amino acids constitute the shortest analog of GHRH, which stimulates the secretion of growth hormone (GH) from the anterior pituitary gland. Consequently, aod9604 and cjc 1295 are distinct peptides possessing different chemical structures.

cjc 1295 binds to receptors located in the pituitary gland, thereby stimulating the secretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) into the plasma. Its mechanism of action is akin to that of sermorelin, as it elevates GH levels by acting on the GHRH receptor. cjc 1295 has demonstrated a series of benefits, including the promotion of deep sleep, the support of muscle mass growth, and the stimulation of fat loss.

AOD 9604 vs sermorelin

Sermorelin is a synthetic peptide containing 29 Amino acids (GHRH 1-29) that mimics the action of naturally occurring growth hormone-releasing hormone (GHRH) composed of 44 Amino acid residues. Sermorelin binds to growth hormone-releasing hormone receptors (GHRHr), thereby stimulating somatotroph cells to increase the production and secretion of growth hormone (GH). Consequently, sermorelin ensures the maintenance of the overall homeostatic balance within the hypothalamus-pituitary-somatotropin axis. The primary role of sermorelin is to restore growth hormone (GH) levels and to delay the aging process.The administration of sermorelin yields secondary benefits, which include enhanced muscle development, accelerated wound healing, reduced body fat, improved sleep quality, enhanced brain function, and cardiovascular growth. Therefore, AOD 9604 and sermorelin are essentially distinct peptides derived from two distinct hormones and the functional spectrum of sermorelin is broader compared to AOD 9604.

Related Peptides at Creative Peptides

FAQ

Is AOD 9604 FDA approved?

AOD 9604 has not been approved by the FDA for use in weight loss, and is instead classified as a research peptide.

What is another name for AOD9604?

Other names for AOD9604 include lipotropin and Tyr-hGH fragment.

References

1. Ogru E., et al., The conformational and biological analysis of a cyclic anti-obesity peptide from the C-terminal domain of human growth hormone. J Pept Res. 2000 ,56(6):388-97.
2. Margret I.M.,David K., Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. J. Clin. Endocrinol. Metab. 2014,4(3):64-77
3. Ahmadian M.,Wang Y.H., Sul H.S., Medicine in Focus: Lipolysis in Adipocytes Int J Biochem Cell Biol. 2010, 42(5): 555–559.